Hepatitis B Vaccination Recommended
A patient with HBsAg negative and anti-HBs 0 (negative) is susceptible to hepatitis B virus infection and should receive the complete hepatitis B vaccine series. 1
Immediate Management
This serologic profile (HBsAg negative, anti-HBs negative) indicates:
- No current HBV infection (HBsAg negative)
- No immunity to HBV (anti-HBs negative)
- Complete susceptibility to hepatitis B infection
The patient requires vaccination with the standard hepatitis B vaccine series.
Vaccination Protocol
Administer the complete 3-dose hepatitis B vaccine series:
- Doses given at 0,1, and 6 months
- Use standard adult dosing (typically 20 mcg for most vaccines)
Post-vaccination testing is essential 1:
- Test for anti-HBs 1-2 months after the final dose
- Use a method that determines protective antibody concentration
- Protective level: anti-HBs ≥10 mIU/mL
Post-Vaccination Management Algorithm
If anti-HBs ≥10 mIU/mL after primary series:
- Patient is considered immune
- No further periodic testing needed in immunocompetent persons
- Long-term protection is established 1
If anti-HBs <10 mIU/mL after primary series:
- Revaccinate with a complete second 3-dose series
- Retest anti-HBs 1-2 months after the final dose of the second series 1
If anti-HBs remains <10 mIU/mL after second series:
- Test for HBsAg to rule out chronic infection
- If HBsAg negative: patient is a non-responder and susceptible to HBV
- Counsel about precautions to prevent HBV infection
- Requires HBIG post-exposure prophylaxis for any known exposure to HBsAg-positive sources 1
Special Considerations
High-priority vaccination candidates who require post-vaccination testing 1:
- Healthcare workers with blood/body fluid exposure risk
- Hemodialysis patients
- HIV-infected or immunocompromised persons
- Sexual partners of HBsAg-positive persons
- Persons with occupational blood exposure risk
Common pitfall: Do not delay vaccination while waiting for additional testing. The first dose should be administered immediately if the patient is at risk for HBV exposure.
Important note: The presence of anti-HBs provides protection against HBV infection, as demonstrated in transplant populations where anti-HBs(+) patients had significantly lower infection rates (1.2%) compared to anti-HBs(-) patients (5.6%) 2. This underscores the critical importance of achieving protective antibody levels through vaccination.